Fust Matthew K
SEC CIK 1397266 · EDGAR
BoughtSold
Most active insiders at ATRA, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | EcoR1 Capital, LLC | 10% | $4.74M | — |
| 2 | Panacea Innovation Ltd | 10% | — | $3.17M |
| 3 | Cherry Brian N | Dir | $1000.0K | — |
| 4 | Huang James | Dir, 10% | — | $489.0K |
| 5 | Nguyen AnhCo | Pres, CEO, Dir | — | $142.4K |
| 6 | Grant-Huerta Yanina | CAO | — | $56.5K |
| 7 | Ciongoli Gregory Austin | Dir, 10%, See Remarks | — | — |
| 8 | Redmile Group, LLC | Dir | — | — |
| 9 | Fust Matthew K | Dir | — | — |
| 10 | HEIDEN WILLIAM K | Dir | — | — |
Transactions 17
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-11 16:36 | 2026-06-09 | ATRA | Atara Biotherapeutics, Inc. | Fust Matthew K | Dir | A - Grant | $0.00 | +12.0K | 30.2K | +66% | $0 | |
| D | 2026-05-18 18:50 | 2026-05-14 | RARE | Ultragenyx Pharmaceutical Inc. | Fust Matthew K | Dir | A - Grant | $0.00 | +7,751 | 33.7K | +30% | $0 |
| 2025-06-12 | 2025-06-10 | ATRA | Atara Biotherapeutics, Inc. | Fust Matthew K | Dir | A - Grant | $0.00 | +7,828 | 18.2K | +76% | $0 | |
| D | 2025-05-19 | 2025-05-15 | RARE | Ultragenyx Pharmaceutical Inc. | Fust Matthew K | Dir | A - Grant | $0.00 | +5,740 | 25.9K | +28% | $0 |
| DMT | 2024-10-18 | 2024-10-17+ | NMRA | Neumora Therapeutics, Inc. | Fust Matthew K | Dir | M - OptEx | $5.83 | +21.8K | 34.1K | +176% | +$127.0K |
| DMT | 2024-10-18 | 2024-10-17+ | NMRA | Neumora Therapeutics, Inc. | Fust Matthew K | Dir | S - Sale+OE | $17.02 | -21.8K | 20.1K | -52% | -$370.9K |
| D | 2024-06-20 | 2024-06-18 | RARE | Ultragenyx Pharmaceutical Inc. | Fust Matthew K | Dir | A - Grant | $0.00 | +5,345 | 20.2K | +36% | $0 |
| D | 2024-06-14 | 2024-06-13 | NMRA | Neumora Therapeutics, Inc. | Fust Matthew K | Dir | A - Grant | $0.00 | +20.1K | 20.1K | New | $0 |
| 2024-04-02 | 2024-03-31 | ATRA | Atara Biotherapeutics, Inc. | Fust Matthew K | Dir | A - Grant | $0.00 | +150.0K | 259.0K | +138% | $0 | |
| MT | 2024-03-11 | 2024-03-07 | RARE | Ultragenyx Pharmaceutical Inc. | Fust Matthew K | Dir | S - Sale | $50.88 | -12.2K | 14.9K | -45% | -$620.4K |
| D | 2023-06-09 | 2023-06-07 | RARE | Ultragenyx Pharmaceutical Inc. | Fust Matthew K | Dir | D - Sale to Iss | $51.82 | -3,300 | 27.1K | -11% | -$171.0K |
| D | 2023-06-09 | 2023-06-07 | RARE | Ultragenyx Pharmaceutical Inc. | Fust Matthew K | Dir | A - Grant | $0.00 | +3,860 | 30.4K | +15% | $0 |
| D | 2023-06-02 | 2023-05-31 | ATRA | Atara Biotherapeutics, Inc. | Fust Matthew K | Dir | A - Grant | $0.00 | +57.0K | 109.0K | +110% | $0 |
| D | 2022-06-28 | 2022-06-24 | RARE | Ultragenyx Pharmaceutical Inc. | Fust Matthew K | Dir | A - Grant | $0.00 | +3,300 | 26.5K | +14% | $0 |
| D | 2022-06-27 | 2022-06-23 | ATRA | Atara Biotherapeutics, Inc. | Fust Matthew K | Dir | A - Grant | $0.00 | +20.5K | 52.0K | +65% | $0 |
| D | 2022-03-08 | 2022-03-04 | RARE | Ultragenyx Pharmaceutical Inc. | Fust Matthew K | Dir | M - OptEx | $40.37 | +7,500 | 23.2K | +48% | +$302.8K |
| 2021-11-05 | 2021-11-04 | ATRA | Atara Biotherapeutics, Inc. | Fust Matthew K | Dir | S - Sale | $19.50 | -13.4K | 31.5K | -30% | -$260.4K |
Purchase Sale Sale after option exercise All abbreviations